Cash Flow Statement

Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Growth Metrics

Others

Ratios

Lyra Therapeutics (LYRA) Amortizatization of Intangibles (2023 - 2024)

Lyra Therapeutics has reported Amortizatization of Intangibles over the past 2 years, most recently at $267000.0 for Q4 2024.

Quarterly results put Amortizatization of Intangibles at $267000.0 for Q4 2024, down 75.46% from a year ago — trailing twelve months through Dec 2024 was $2.3 million (down 34.9% YoY), and the annual figure for FY2024 was $2.3 million, down 34.9%.
Amortizatization of Intangibles for Q4 2024 was $267000.0 at Lyra Therapeutics, down from $401000.0 in the prior quarter.
Over the last five years, Amortizatization of Intangibles for LYRA hit a ceiling of $1.1 million in Q4 2023 and a floor of $267000.0 in Q4 2024.